PHARMAENGINE, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 97.9 TWD | +2.94% |
|
+4.93% | -7.20% |
| 05-02 | PharmaEngine, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 04-24 | PharmaEngine, Inc. Announces First Patient Dosed in Phase I Trial of PEP07 for Solid Tumors | CI |
Evolution of the average Target Price on PharmaEngine, Inc.
Price target over the last 5 years
History of analyst recommendation changes
a6a0be506531a80d.Lxk6zOvBNskIOpIB1kLsYC_fyNi8C-1q4o1gvOXdky4.e01znNuVXapOD9hrmwPcVl3mq4v0WLg1uLQkj42TqhxoTVithYdsrFFPww~c93432c0272892870748e00059227d52
Analysts' Consensus
Sell
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
97.9
TWD
Average target price
106
TWD
Spread / Average Target
+8.27%
High Price Target
106
TWD
Spread / Highest target
+8.27%
Low Price Target
106
TWD
Spread / Lowest Target
+8.27%
Consensus detail
Consensus revision (last 18 months)
Trading Rating
Investor Rating
ESG Refinitiv
EPS Revisions
- Stock Market
- Equities
- 4162 Stock
- Consensus PharmaEngine, Inc.
